UK Renal Registry, Southmead Hospital, Bristol, UK.
Nephron Clin Pract. 2011;119 Suppl 2:c27-52. doi: 10.1159/000331744. Epub 2011 Aug 26.
This chapter describes the characteristics of adult patients on renal replacement therapy (RRT) in the UK in 2009. The prevalence rates per million population (pmp) were calculated for Primary Care Trusts in England, Health and Social Care Areas in Northern Ireland, Local Health Boards in Wales and Health Boards in Scotland. These areas will be referred to in this report as 'PCT/HBs'.
Data were electronically collected from all 72 renal centres within the UK. A series of cross-sectional and longitudinal analyses were performed to describe the demographics of prevalent RRT patients in 2009 at centre and national level. Age and gender standardised ratios for prevalence rates in PCT/HBs were calculated.
There were 49,080 adult patients receiving RRT in the UK on 31st December 2009, equating to a UK prevalence of 794 pmp. This represented an annual increase in prevalent numbers of approximately 3.2% although there was significant variation between centres and PCT/HB areas. The growth rate from 2008 to 2009 for prevalent patients by treatment modality in the UK was 4.2% for haemodialysis (HD), a fall of 7.2% for peritoneal dialysis (PD) and a growth of 4.4% with a functioning transplant. There has been a slow but steady decline in the proportion of PD patients from 2000 onwards. Median RRT vintage was 5.4 years. The median age of prevalent patients was 57.7 years (HD 65.9 years, PD 61.2 years and transplant 50.8 years). For all ages, prevalence rates in males exceeded those in females: peaks for males were in the 75-79 years age group at 2,632 pmp and for females in the 70-74 years age group at 1,445 pmp. The most common identifiable renal diagnosis was biopsy-proven glomerulonephritis (16.0%), followed by diabetes (14.7%). Transplantation was the most common treatment modality (48%), HD in 44% and PD 8%. However, HD was increasingly common with increasing age and transplantation less common.
The HD and transplant population continued to expand whilst the PD population contracted. There were national, regional and dialysis centre level variations in prevalence rates. This has implications for service planning and ensuring equity of care for RRT patients.
本章描述了 2009 年英国接受肾脏替代治疗（RRT）的成年患者的特征。每百万人口（pmp）的患病率率在英格兰的初级保健信托、北爱尔兰的卫生和社会保健区、威尔士的地方卫生委员会和苏格兰的卫生委员会进行了计算。在本报告中，这些地区将被称为“PCT/HBs”。
从英国的 72 个肾脏中心电子收集数据。对中心和国家一级 2009 年现有 RRT 患者的人口统计学数据进行了一系列横断面和纵向分析。按年龄和性别对 PCT/HBs 的患病率率进行了标准化比值计算。
2009 年 12 月 31 日，英国有 49080 名成年患者接受 RRT，英国患病率为 794 pmp。这意味着现有患者数量的年增长率约为 3.2%，尽管中心和 PCT/HB 地区之间存在显著差异。英国按治疗方式划分的 2008 年至 2009 年期间，新发病例的增长率为血液透析（HD）4.2%，腹膜透析（PD）下降 7.2%，功能移植增长 4.4%。自 2000 年以来，PD 患者的比例一直在缓慢但稳步下降。中位 RRT 治疗年限为 5.4 年。现有患者的中位年龄为 57.7 岁（HD 为 65.9 岁，PD 为 61.2 岁，移植为 50.8 岁）。对于所有年龄段，男性的患病率均高于女性：男性的患病率峰值在 75-79 岁年龄组，为 2632 pmp，女性在 70-74 岁年龄组，为 1445 pmp。最常见的明确肾脏诊断是活检证实的肾小球肾炎（16.0%），其次是糖尿病（14.7%）。移植是最常见的治疗方式（48%），HD 为 44%，PD 为 8%。然而，HD 随着年龄的增长而变得越来越普遍，而移植则越来越少。
HD 和移植人群继续扩大，而 PD 人群则收缩。在患病率率方面存在国家、地区和透析中心层面的差异。这对服务规划和确保 RRT 患者的护理公平性具有影响。
